Jonathan Baell (né Ball) is trained as an Australian medicinal chemist and is currently executive director, early leads chemistry at Lyterian Therapeutics in San Francisco. Prior to this, he was a research professor in medicinal chemistry at the Monash Institute of Pharmaceutical Sciences (MIPS),[1] the director of the Australian Translational Medicinal Chemistry Facility[2] and a Chief Investigator at the ARC Centre for Fragment-Based Design.[3] He was President of the International Chemical Biology Society 2018-2021 and is currently chair of the board.[4] His research focuses on the early stages of drug discovery, including high-throughput screening (HTS) library design, hit-to-lead and lead optimization for the treatment of a variety of diseases, such as malaria and neglected diseases.[5]
- ^ "Jonathan Baell". Monash University. Retrieved 28 July 2020.
- ^ "Our Team and Contacts". Australian Translational Medicinal Chemistry Facility. Retrieved 28 July 2020.
- ^ "Chief Investigators". ARC Centre for Fragment-Based Design. 16 April 2020. Retrieved 28 July 2020.
- ^ "ICBS Leadership - International Chemical Biology Society". www.chemical-biology.org. Retrieved 28 July 2020.
- ^ "Prof. Jonathan Baell of "PAINS" Filters Fame from Monash University". Collaborative Drug Discovery Inc. (CDD). 7 October 2013. Retrieved 28 July 2020.